Ostatné · INDV
Indivior Pharmaceuticals, Inc.
Fundamenty firmy Healthcare · Drug Manufacturers - Specialty & Generic · United States
Hodnotenie 0–10, vypočítané z údajov firmy
Analytici 4 hodnotení
–
- Najnižší cieľ
- 43,00
- Priemerný cieľ
- 49,00
- Najvyšší cieľ
- 53,00
- Potenciál
- +36,2 %
Odhad zisku na akciu (EPS)
| Obdobie | Odhad | Rozpätie | Pred rokom | Rast |
|---|---|---|---|---|
| tento štvrťrok | 1,12 | 1,09–1,15 | 0,72 | +55,4 % |
| budúci štvrťrok | 1,21 | 1,21–1,22 | 0,82 | +48,1 % |
| tento rok | 4,41 | 4,36–4,47 | 2,50 | +76,3 % |
| budúci rok | 4,88 | 4,74–5,02 | 4,41 | +10,8 % |
Odhad tržieb
| Obdobie | Odhad | Pred rokom | Rast |
|---|---|---|---|
| tento štvrťrok | 329,4 mil. | 314,0 mil. | +4,9 % |
| budúci štvrťrok | 337,9 mil. | 358,0 mil. | −5,6 % |
| tento rok | 1,3 mld. | 1,2 mld. | +7,5 % |
| budúci rok | 1,4 mld. | 1,3 mld. | +5,1 % |
Nákupy a predaje manažérov insider
| Kto | Čo | Hodnota | Dátum |
|---|---|---|---|
| Blackrock, Inc. | iná transakcia | – | 27.06. |
| Millennium International Management Lp | iná transakcia | – | 27.06. |
| Millennium International Management Lp | iná transakcia | – | 16.06. |
| Thompson (Juliet) | iná transakcia | 26 719 | 11.06. |
| Thompson (Juliet) | iná transakcia | 53 438 | 11.06. |
| Millennium International Management Lp | iná transakcia | – | 09.06. |
| Millennium International Management Lp | iná transakcia | – | 05.06. |
| Stejbach (Mark P.) | iná transakcia | 12 000 | 05.05. |
| Rubric Capital Master Fund Lp | iná transakcia | – | 21.04. |
| Rubric Capital Master Fund Lp | iná transakcia | – | 02.04. |
| Millennium International Management Lp | iná transakcia | – | 25.03. |
| Rubric Capital Master Fund Lp | iná transakcia | – | 19.03. |
Kto vlastní akcie
Slávni investori: Howard Marks · 4.7 % · nový Ray Dalio · 0.0 %
Blackrock Inc.15,85 %
Vanguard Portfolio Management LLC6,42 %
Oaktree Capital Management LP5,19 %
Vanguard Capital Management LLC4,66 %
State Street Corporation4,23 %
Fuller & Thaler Asset Management Inc.3,91 %
Two Seas Capital Lp2,95 %
Morgan Stanley2,88 %
O firme (popis z Yahoo Finance, anglicky)
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Názor AI
Krátke zhodnotenie trendu, správ a blížiacich sa udalostí.
Technické signály
- Pri SMA200 – Kurz testuje 200-dňový priemer – dôležitá úroveň
Odporúčania
K tomuto aktívu zatiaľ nemáme odporúčanie.
Predikcie
Žiadne predikcie.
Súvisiace správy
Žiadne správy so značkou INDV.